|
| Press Releases |
|
 |
|
| Wednesday, July 31, 2024 |
|
|
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at AAIC 2024 |
| Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings for lecanemab-irmb (U.S. brand name: LEQEMBI), an anti-amyloid beta (Abeta) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference (AAIC) 2024, held in Philadelphia, and virtually. more info >> |
|
| Monday, July 29, 2024 |
|
|
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Marketing Authorization Approval (MAA) for the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab as treatment for early AD (mild cognitive impairment due to Alzheimer?s disease (AD) and mild AD). more info >> |
|
| Thursday, July 25, 2024 |
|
|
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration |
| Eisai Co., Ltd. and EcoNaviSta Inc. announced today that they have entered into a business alliance agreement and commenced collaboration with the aim of building an ecosystem in the area of dementia, which is a pressing matter in Japan's super-aging society. more info >> |
|
| Tuesday, July 23, 2024 |
|
|
Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024 |
| The conference will be held in Philadelphia and virtually from July 28 to August 1, 2024. Eisai will present data and research in four (4) oral and 15 poster presentations at the meeting and will host two (2) sessions on lecanemab. more info >> |
|
| Tuesday, July 16, 2024 |
|
|
エーザイ、ホスラブコナゾールのアジア・オセアニアにおけるライセンス契約を佐藤製薬と締結 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、抗真菌剤ホスラブコナゾールについて、真菌性疾患に対するアジア・オセアニアにおける開発および商業化に関するライセンス契約を佐藤製薬株式会社（本社：東京都、以下 佐藤製薬）と締結したことをお知らせします。 more info >> |
|
| Friday, July 12, 2024 |
|
|
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel |
| Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (generic name: lecanemab) has been approved in Israel as a treatment of Alzheimer's disease (AD). more info >> |
|
|
エーザイとバイオジェン、「レケンビ」（レカネマブ）がイスラエルにおいてアルツハイマー病治療剤として承認を取得 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫、以下 エーザイ）と バイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、 CEO：Christopher A. Viehbacher、以下 バイオジェン）は、このたび、ヒト化抗ヒト可溶性アミロイドβ（Aβ）凝集体モノクローナル抗体「レケンビ®」（一般名：レカネマブ）について、イスラエルにおいて新薬承認を取得したことをお知らせします。 more info >> |
|
| Thursday, July 11, 2024 |
|
|
LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated amyloid-beta (Abeta;) monoclonal antibody "LEQEMBI" (brand name in Hong Kong: generic name: lecanemab) for treatment of Alzheimer's disease (AD). more info >> |
|
|
エーザイとバイオジェン、「LEQEMBI」（レカネマブ）が香港においてアルツハイマー病治療剤として承認を取得 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫、以下 エーザイ）と バイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、 CEO：Christopher A. Viehbacher、以下 バイオジェン）は、このたび、ヒト化抗ヒト可溶性 アミロイドβ（Aβ）凝集体モノクローナル抗体「レケンビ(R)」（香港製品名：「樂意保(R)」、一般名：レカネマブ）について、香港衛生署（Department of Health）より新薬承認を取得したことをお知らせします。 more info >> |
|
| Tuesday, July 2, 2024 |
|
|
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) |
| Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), formerly known as MORAb-202, a folate receptor alpha (FRα)-targeting antibody drug conjugate (ADC) due to ongoing portfolio prioritization efforts within Bristol Myers Squibb. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
遇见小面首份财报出炉：2025年收入净利双增 ESG实践助力长期价值
Apr 29, 2026 14:44 HKT/SGT
|
|
|
The Fifth International Healthcare Week set for next month, to highlight Hong Kong's position as medical technology and investment hub
Apr 29, 2026 12:37 HKT/SGT
|
|
|
CTF Life Title Sponsors 'Fencing Plus' Training Programme 2026 Organised by Kai Tak Sports Initiative
Apr 29, 2026 11:07 HKT/SGT
|
|
|
周大福人壽冠名贊助：飛越啟德「小劍神」培訓計劃2026
Apr 29, 2026 11:07 HKT/SGT
|
|
|
周大福人寿冠名贊助：飞越启德「小剑神」培训计划2026
Apr 29, 2026 11:07 HKT/SGT
|
|
|
隨著歐洲與東南亞吸納越來越多國際護理人員，全球護理人員遷徙模式正發生轉變
Apr 28, 2026 22:00 HKT/SGT
|
|
|
随着欧洲和东南亚吸纳的国际护士比例不断上升，全球护士流动格局正在发生变化
Apr 28, 2026 22:00 HKT/SGT
|
|
|
Global Nurse Migration Patterns Shift as Europe, Southeast Asia Absorb Growing Share of International Nurses
Apr 28, 2026 22:00 HKT/SGT
|
|
|
Tenstorrent、新たなネットワーク型AIアーキテクチャ上で展開される業界最高水準の性能により大規模AIを実現
Apr 28, 2026 22:00: JST
|
|
|
Tenstorrent Enables AI At Scale with Industry-Leading Performance Deployed on Novel Networked AI Architecture
Apr 28, 2026 21:00 HKT/SGT
|
|
|
TANAKA to Showcase Advanced Semiconductor Materials and Circular Economy Initiatives at SEMICON Southeast Asia 2026
Apr 28, 2026 21:00 JST
|
|
|
HKTDC's response to Hong Kong's export figures for March
Apr 28, 2026 19:23 HKT/SGT
|
|
|
CanSinoBIO Delivers Q1 Revenue Growth Amid Accelerating International Expansion
Apr 28, 2026 19:11 HKT/SGT
|
|
|
康希諾生物一季度業績穩健增長 全生命週期佈局打開長期價值空間
Apr 28, 2026 19:04 HKT/SGT
|
|
|
Kincora Commences Drilling at the Historic Condobolin Mining Field
Apr 28, 2026 19:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
